BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 18570858)

  • 1. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Jager PL; Gietema JA; van der Graaf WT
    Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
    J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18 FDG PET imaging in gastrointestinal stromal tumor.
    Reddy MP; Reddy P; Lilien DL
    Clin Nucl Med; 2003 Aug; 28(8):677-9. PubMed ID: 12897659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor].
    Delgado Bolton RC; Ortega Candil A; Pérez Castejón MJ; Garcerant M; Cabrera Martín MN; Lapeña Gutiérrez L; Carreras Delgado JL
    Rev Esp Med Nucl; 2008; 27(2):112-7. PubMed ID: 18367049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
    Zincirkeser S; Sevinc A; Kalender ME; Camci C
    World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
    Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
    Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA; Nair N
    Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
    [No Abstract]   [Full Text] [Related]  

  • 17. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
    Shinto A; Nair N; Dutt A; Baghel NS
    Clin Nucl Med; 2008 Jul; 33(7):486-7. PubMed ID: 18580237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
    Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    Stroobants S; Goeminne J; Seegers M; Dimitrijevic S; Dupont P; Nuyts J; Martens M; van den Borne B; Cole P; Sciot R; Dumez H; Silberman S; Mortelmans L; van Oosterom A
    Eur J Cancer; 2003 Sep; 39(14):2012-20. PubMed ID: 12957455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophageal gastrointestinal stromal tumor: report of 7 patients.
    Shinagare AB; Zukotynski KA; Krajewski KM; Jagannathan JP; Butrynski J; Hornick JL; Ramaiya NH
    Cancer Imaging; 2012 Apr; 12(1):100-8. PubMed ID: 22542728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.